BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Month: February 2022

3 posts
Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • BioTech Health X
  • February 28, 2022
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
0 Shares
0
0
0
0
0
0
0
Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team

Biotech NewsCellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs

  • BioTech Health X
  • February 10, 2022
With the appointments of these experts, the firm has added to its industry knowledge, including Chief Scientific Officer…
0 Shares
0
0
0
0
0
0
0
BioTech Health X CEO Series Virios Therapeutics Greg Duncan

BioTech CEO InterviewsBioTech Health X CEO Series: Virios Therapeutics Greg Duncan

  • BioTech Health X
  • February 1, 2022
BioTech Health X works to deliver the latest coverage and updates in the biotechnology sector. This includes providing…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • GE HealthCare (GEHC) Has a $23.9 Billion Reason for Investors to Look Twice
  • Tempus AI (TEM) Just Hit $382.5 Million in Revenue—Should Investors Care?
  • RadNet (RDNT)’s AI Revenue Just Surged 56.5%—Is RDNT Ready for Its Next Scan?
  • Certara (CERT) Is Under $8—Is This Quiet AI Healthcare Play Ready to Wake Up?
  • Butterfly Network (BFLY) Wants to Put an Ultrasound in Every Pocket—Could BFLY Soar?
Featured Posts
    • September 12, 2026
    GE HealthCare (GEHC) Has a $23.9 Billion Reason for Investors to Look Twice
    • September 12, 2026
    Tempus AI (TEM) Just Hit $382.5 Million in Revenue—Should Investors Care?
    • September 12, 2026
    RadNet (RDNT)’s AI Revenue Just Surged 56.5%—Is RDNT Ready for Its Next Scan?
    • September 12, 2026
    Certara (CERT) Is Under $8—Is This Quiet AI Healthcare Play Ready to Wake Up?
    • September 12, 2026
    Butterfly Network (BFLY) Wants to Put an Ultrasound in Every Pocket—Could BFLY Soar?
Recent Posts
  • SOPHiA GENETICS (SOPH) Wants to Crack Cancer’s Genetic Code
    • September 12, 2026
  • Schrödinger (SDGR)’s Paradox: Is This AI Drug Pick Both Cheap and Expensive?
    • September 12, 2026
  • Recursion (RXRX) Is Under $5—Could RXRX Be an AI Biotech Sleeper?
    • September 12, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (1,064)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top